Sialanar

RSS

glycopyrronium

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Sialanar. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Sialanar.

For practical information about using Sialanar, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 04/04/2018

Authorisation details

Product details
Name
Sialanar
Agency product number
EMEA/H/C/003883
Active substance
Glycopyrronium bromide
International non-proprietary name (INN) or common name
glycopyrronium
Therapeutic area (MeSH)
Sialorrhea
Anatomical therapeutic chemical (ATC) code
A03AB02
Publication details
Marketing-authorisation holder
Proveca Limited
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
14/09/2016
Contact address
Neo
Charlotte Street
Manchester
M1 4ET
United Kingdom

Product information

11/05/2017 Sialanar - EMEA/H/C/003883 - IAIN/0003

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

Therapeutic indication

Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.

Assessment history

How useful was this page?

Add your rating